Eliminating MDM4 and MDM2 by MMRi62 hits the key drug targets in AML because MDM4 is a pervasive driver of leukemogenesis in multiple mouse leukemia models (44), and MDM2 overexpression induced by MTF2 loss is a mediator for refractory AML (45). Here, MTF2 is linked to acute myeloid leukemia.